Lenalidomide

(Revlimid)

Lenalidomide

Drug updated on 8/25/2023

Dosage FormCapsule (oral; 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg)
Drug ClassThalidomide analogue
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of multiple myeloma (MM), in combination with dexamethasone.
  • For the treatment of MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT).
  • For the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.
  • For the treatment of mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
  • For the treatment of previously treated follicular lymphoma (FL), in combination with a rituximab product.
  • For the treatment of previously treated marginal zone lymphoma (MZL), in combination with a rituximab product.

Product Monograph / Prescribing Information

Document TitleYearSource
Revlimid (lenalidomide) Prescribing Information.2023Bristol-Myers Squibb Company, Princeton, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines